|Last Price$48.05||Day Change (%)1.33%|
|Open Price$46.73||Day Change ($)0.63|
|Day Range46.55–48.39||52-Week Range44.80–76.68|
As of Fri 9/4/2015 5:00:00 PM | USD
Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo
Mylan Clarifies Certain Inaccuracies by Third Parties Related to Lowered Acceptance Condition to Acquire Perrigo
Mylan Responds to ISS Recommendation Regarding Perrigo Transaction
Mylan Statement in Response to FDA Warning Letter Relating to Certain Agila Facilities
Paulson & Co. Votes in Support of Mylan's Proposed Merger with Perrigo
Egan-Jones Joins Glass Lewis in Recommending Mylan Shareholders Vote For Perrigo Transaction Proposal
Watson Pharmaceuticals WPI scored big Tuesday when the Food and Drug Administration approved the firm's generic fentanyl patch. We may modestly increase our fair value estimate for Watson and will maintain our fair value estimate for competitor Mylan Laboratories MYL . The pain patch is one of the ...
Mylan Laboratories MYL reported impressive second-quarter results Wednesday. However, most of the improvement was temporary and will not affect our fair value estimate. The quarter was only slightly better than we expected after excluding a one-time litigation payment and proceeds from a product ...
Research and Markets: Global Markets for Drug Delivery: Transdermal and Inhalation Drug Delivery Technologies in 2015
Proxy Adviser Says Mylan Holders Should Shun Perrigo Deal